Neoplasms, Plasma Cell D054219

Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Plasma Cell

Description

Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.   MeSH

Hierarchy View

Subtype Terms (4)

Immunoglobulin Light-chain Amyloidosis
54 drugs (40 approved, 14 experimental)

Multiple Myeloma
860 drugs (291 approved, 569 experimental)

Plasmacytoma
86 drugs (59 approved, 27 experimental)

Waldenstrom Macroglobulinemia
171 drugs (92 approved, 79 experimental)


Phase 3 Indicated Drugs (2)


Organization Involved with Phase 3 Indications (221)

Fondazione Neoplasie Sangue Onlus

François Rabelais University

Freeman Health System

Friedrich Schiller University

Gazi University

Genentech

Genta

Genzyme

Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

GlaxoSmithKline

Government of France

Government of Norway

Grupo Cooperativo de Hemopatías Malignas

Grupo de Estudos Multicentricos em Onco-Hematologia

Gruppo Italiano Malattie EMatologiche dell'Adulto

Gruppo Italiano per lo Studio del Mieloma Multiplo

Guangzhou Medical University

Guthrie Clinic

Hoosier Cancer Research Network

Hospital Avicenne

Hospital Clinico Madrid

Hospital Doce de Octubre Madrid

Hospital Universitari Son Dureta

HOVON - Dutch Haemato-Oncology Association

Huai'an Second People's Hospital

Icahn School of Medicine at Mount Sinai

I-Mab Biopharma

Imperial College London

Institut Paoli-Calmettes

Intergroupe Francophone du Myelome

International Myeloma Foundation (IMF)

James R. Berenson MD, Inc.

Janssen Pharmaceutica NV

Jiangnan University

Jiangyin People's Hospital

Jingjiang People's Hospital

Jinlin University

Johns Hopkins University

Julius-Maximilians University

Karyopharm Therapeutics Inc

King Faisal University

Kunming Medical University

Laphal

Marche Polytechnic University

Maria Sklodowska Curie Children's Hospital

Marshall University

Mayo Clinic

McMaster University

Medical College of Wisconsin

Medical Research Council

Medsearch

Merck

Metro-Minnesota

Molinette Hospital

Myeloma Institute for Research & Therapy

Nanjing Medical University

Organization Involved with Phase 2 Indications (320)

Aalborg University

Academic and Community Cancer Research United

Academic Myeloma Consortium

Accelovance

Adaptimmune

Adknoma Health Research

Aduro BioTech

Advent Health

Albert Schweitzer Ziekenhuis

Alexandra Hospital, Athens, Greece

Alexion

Alliance Foundation Trials

Altor Bioscience

American Cancer Society, Inc.

American Society of Clinical Oncology

AmpliMed Corporation

AnorMED

Antengene Corporation

AOI Pharmaceuticals, Inc.

Apogee Biotechnology Corporation

Arbeitsgemeinschaft medikamentoese Tumortherapie

Arch Oncology

Aristotle University of Thessaloniki

Array BioPharma

Assign Clinical Research GmbH

Astellas

Astex Pharmaceuticals, Inc.

Attenuon

Autolus Limited

Azienda Ospedaliera Universitaria Senese

Bayer

Beckloff Associates, Inc.

Bethanien hospital, Frankfurt

Biogen

Biohaven Pharmaceuticals Inc.

BioInvent International AB

Biokine Therapeutics Ltd

Biologics, Inc.

Bioscience, S.A.

Biotest Pharmaceuticals

Bloodwise

Boston University

Brown University

Burzynski Research Institute

Callisto Pharmaceuticals

Cancer Biotherapy Research Group

Cancer Treatment Centers of America

Cancer Trials Ireland

Cantonal Hospital of St. Gallen

Cardiff University

CARsgen Therapeutics, Ltd.

Cartesian Therapeutics

CASI Pharmaceuticals, Inc.

Cell Genesys

Celularity, Inc.

Central Hospital of Kanta-Hame

Centre de Commercialisation en Immunothérapie du Cancer

Centre de Commercialisation en Immunothérapie du Cancer (C3i)

Centre Hospitalier de Blois -BLOIS

Centre Leon Berard

Chang Gung University

China Food and Drug Administration

Chipscreen Biosciences, Ltd.

Chongqing Medical University

Chongqing Precision Biotech Co., Ltd

Chonnam National University

Christian Medical College, Vellore, India

Chroma Therapeutics

Ciusss de L'Est de l'Île de Montréal

Clinipace LTD

Constant Pharmaceuticals

Criterium, Inc.

CTC Bio, Inc.

CTI BioPharma

CureTech Ltd

Danish Myeloma Study Group

Dartmouth University

Department of Defense

Department of Veteran Affairs

Diverse Biotech

Dutch Cancer Society

Eisai

Eli Lilly

Enceladus Pharmaceuticals BV

Entera Health, Inc

European Commission

European Union

ExcellThera

Exelixis

Fondos ARI

Fondo Social La Caixa

Free University of Amsterdam

Fudan University

Gachon University

Gateway for Cancer Research

Genenta Science S.R.L.

Gennimatas Hospital, Athens

GenScript

German Cancer Research Center

Geron Corporation

Gilead Sciences

Gleneagles CRC

Gleneagles Hospital, Singapore

GlycoMimetics, Inc.

Government of Canada

Government of Finland

Government of Japan

Government of Singapore

Gruppo Italiano Studio Linfomi

GWT-TUD GmbH

Hackensack University Medical Center

Harpoon Therapeutics

HeaDS

Heidelberg Clinical Research Centre

Hellenic Society of Hematology

Helsinn

Henan Medical University

Herbert Irving Comprehensive Cancer Center

Hoag Memorial Hospital Presbyterian

HOANNJ-Carol G. Simon Cancer Center

Horizon Health Network

Hospital Universitario Reina Sofía

Huazhong University of Science and Technology

Human Genome Sciences

Immune Control

Immunomedics

Incyte

Indiana University

Innate Pharma

Institut de Cancerologie de l'Ouest Paul Papin

Institut d'Investigacions Biomèdiques August Pi i Sunyer

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

International Myeloma Foundation

inVentiv

IO Biotech

IQVIA

Isala Clinics, Zwolle, The Netherlands

Italfarmaco

James Berenson Inc.

James Graham Brown Cancer Center

Jilin University

Juno Therapeutics, Inc.

Kantonsspital Graubünden

Kaohsiung Medical University

Karolinska Institute

Katholieke Universiteit Leuven

KCAS Bio

Kleo Pharmaceuticals

Korean Multiple Myeloma Working Party

Korea Research Institute of Bioscience & Biotechnology

Kosin University

Kuopio University Hospital

Kyowa Hakko Kirin

Leo Pharma

LifeTime Pharmaceuticals

Loyola University

Ludwig Institute for Cancer Research

Ludwig Maximilians University

Luzerner Kantonsspital

Maastricht University

Mater Misericordiae University Hospital

Meander Medical Center

Medac

Medical Prognosis Institute A/S

Memorial Sloan-Kettering Cancer Center

Merck KGaA

Methodist Cancer Center, Houston, Texas

Mikkeli Central Hospital

Molecular Partners AG

MolMed S.p.A.

Monash University

Moorgreen Hospital, Southampton

MorphoSys

Multiple Myeloma Research Consortium

Multiple Myeloma Research Foundation

Mundipharma

Myeloma Canada Research Network

Myeloma UK

Nagoya City University

Nanyang Technological University

National Health Service, United Kingdom

National Institutes of Health (NIH)

National Taiwan University

Nerviano Medical Sciences

Netherlands Cancer Institute

New York Medical College

New York University

NexImmune Inc.

Nij Smellinghe Hospital Drachten

Northside Hospital, Inc.

Noxxon AG

OHSU Knight Cancer Institute

Oncoceutics, Inc.

Oncology Venture

OncoPep, Inc.

Onkozentrum Zürich

Onxeo

Ortho Biotech, Inc.

Our Lady of Mercy Medical Center

Parke-Davis

Pavlov First Saint Petersburg State Medical University

Pennsylvania State University

Peter MacCallum Cancer Centre

Pfizer

Pharmacyclics

Piramal

Polish Myeloma Consortium

Polyphor Ltd.

Precision BioSciences, Inc.

Precision Medicine

PrECOG, LLC.

Prolexys Pharmaceuticals

Queen's University, Belfast

Rapa Therapeutics LLC

RedHill Biopharma

Regeneron

Rhode Island Hospital

RIEMSER Arzneimittel GmbH

Rijnstate Hospital

Royal Marsden Hospital NHS Trust

RWTH Aachen University

Scios

SCRI Development Innovations

Seoul National University

Sevion Therapeutics

Shenzhen Geno-Immune Medical Institute

Singapore General Hospital

Sirtris Pharmaceuticals

Smerud Medical Research Denmark

SmithKline Beecham

Sparrow Regional Cancer Center

Spectrum Pharmaceuticals

Sponsor GmbH

State University of New York, Syracuse

Stemline Therapeutics, Inc.

Stony Brook University

Sungkyunkwan University

Swiss Group for Clinical Cancer Research

SymBio Pharmaceuticals

Symphony Capital

TaiGen Biotechnology Co., Ltd.

Taipei Veteran General hospital

Tata Memorial Hospital

Technion University

Tel Aviv University

Telik

Teva

Texas Transplant Institute

TFS Trial Form Support

The Australasian Leukaemia & Lymphoma Group (ALLG)

The Beijing Pregene Science and Technology Company, Ltd.

The Leukemia and Lymphoma Society

Theradex

The University of Hong Kong

The Wayne D. Kuni and Joan E. Kuni Foundation

Thomas Jefferson University

Threshold Pharmaceuticals

Trevie, Inc.

Trinity Health of New England

Triphase Research and Development Corporation

Tufts University

Tzu Chi University

Unicorn Pacific Corporation

Universidad Carlos III Madrid

Universidad de Cordoba

University of Alberta

University of Amsterdam

University of Applied Sciences Würzburg-Schweinfurt

University of Bern

University of Birmingham

University of Cagliari

University of Calgary

University of California, Berkeley

University of Campinas

University of Cologne

University of Colorado, Denver

University of Connecticut

University of Copenhagen

University of Freiburg

University of Hamburg

University of Helsinki

University of Iceland

University of Iowa

University of Kansas

University of London

University of Louisville

University of Maryland, Baltimore County

University of Miami

University of Montreal

University of Nebraska

University of Oslo

University of Oxford

University of Patras

University of Pennsylvania

University of Regensburg

University of Roma La Sapienza

University of Salamanca

University of Seville

University of Southern California

University of Tampere

University of Tennessee

University of Torino

University of Toronto

University of Tuebingen

University of Turku

University of Ulsan

University of Virginia

University of Warwick

University of Wisconsin

Virginia Commonwealth University

Vita-Salute University of Milano. Italy

Vivolux AB

Wilheminenspital

Wyeth

Xcyte Therapies

Yale University

Yeshiva University

Yonsei University

Ziopharm

ZNA Antwerpen

Organization Involved with Phase 1 Indications (106)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.